A Review of the Use of Secukinumab for Psoriatic Arthritis

Abstract

Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (CosentyxÓ) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA. While indirect comparisons of indicate that secukinumab is as effective as other treatment options, further studies directly comparing available treatments will be necessary to establish its place in treatment guidelines. As these and other trials are conducted, the evidence produced will further elucidate the clinical potential of secukinumab as a treatment option for patients with rheumatologic disease.

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

“…AE: adverse event; CEC: Clinical Events Committee; CI: confidence interval; IBD: inflammatory bowel disease; IR: incidence rate; IXE: ixekizumab; MACE: major adverse cardiovascular events; MedDRA: Medical Dictionary for Regulatory Activities; Ns: number of patients entered in each time interval; n: number in group; PBO: placebo; PY: patient-years; Q2W: every 2 weeks; Q4W: every 4 weeks; TEAEs: treatment-emergent adverse events frequent TEAEs [7]; the IR for these events decreased with an increase in the duration of IXE exposure. This is consistent with the pattern observed in the psoriasis clinical trials and with the findings associated with the use of secukinumab in PsA [9,10]. This is similar to the reports for biologic agents neutralizing TNF [11].…”

Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases

“…Preclinical studies have provided promising results in murine models of neutrophilic airway diseases by using IL-17A-or IL-17RA-neutralizing antibodies, indicating that IL-17A signaling inhibition could be a novel therapeutic approach for treatment of these steroid-resistant diseases (3, 6-10). Neutralizing monoclonal antibodies (mAbs) (against IL-17A and IL-17RA) have been developed as candidate drugs targeting IL-17A-dependent pathogenesis (39)(40)(41)(42). However, given the considerable cost of antibody production and limited administration (only through the i.v.…”

Dactylitis in psoriatic arthritis: clinical features, diagnosis, immunopathogenesis, and treatment

“…В последнее время для лечения ПсА активно используется СКМ -моноклональное антитело к ИЛ17А. В ряде исследований отмечена его эффективность в отношении снижения активности дактилита [58,59]. В исследовании FUTURE 1 пациенты получали внутривенную нагрузочную дозу СКМ 10 мг/кг на 0; 2 и 4-й неделях, а с 8-й недели препарат вводили подкожно в дозе 150 или 75 мг 1 раз в 4 нед.…”